Logo

Helsinn Entered into an Exclusive License and Distribution Agreement with Immedica to Commercialize Akynzeo and Aloxi

Share this
Helsinn

Helsinn Entered into an Exclusive License and Distribution Agreement with Immedica to Commercialize Akynzeo and Aloxi

Shots:

  • The companies collaborated to commercialize two cancer supportive care products i.e., Akynzeo (netupitant-palonosetron fixed combination) and Aloxi (palonosetron) for the prevention of CT-induced nausea and vomiting in core EU markets
  • Immedica will be responsible to commercialise Akynzeo in Portugal, Spain, France, Switzerland, the Netherlands, Belgium, Luxembourg & Liechtenstein while ALOXI in Switzerland, Belgium, Liechtenstein
  • Akynzeo is the first 5-HT3 and NK1 receptor antagonist fixed combination & Aloxi has been approved in the EU for the same indication. Akynzeo & Aloxi is currently available in 60+ & 40+ countries, respectively

Ref: Globenewswire | Image: Helsinn

Related News:- Juniper Entered into an Exclusive License Agreement with Helsinn for Ledaga (chlormethine) to Treat Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions